drugset / Trial / NCT03843749

Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

NCT03843749

Unknown 30 enrolled Shanghai Changzheng Hospital
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

Timeline

Start
2019-07-01
Primary completion
2019-07-01
Completion
2022-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pyrotinib Small molecule
Background Trastuzumab Monoclonal antibody

Indications